跳至主要内容
临床试验/NCT01049685
NCT01049685Unknown4 期

Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy in Brazil: a "Real Life" Study

UPECLIN HC FM Botucatu Unesp1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2006年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
发起方
入组人数
36
试验地点
1
主要终点
Maintenance HIV RNA <50 copies/mL at the end oh 36 months

研究概览

简要总结

Retrospective longitudinal cohort study with 36 HIV naïve-treatment patients, who started therapy with lopinavir/ritonavir or efavirenz (LPV/r or EFZ), follow-up of 36 months. Primary endpoint: virological success (HIV RNA <50 copies/mL) in the first six months and at the end of the study.

详细描述

Background: Either LPV/r or EFZ plus a two nucleoside reverse-transcriptase inhibitors (NRTIs) are recommended by the current guidelines all around the world as the main background drugs for initial therapy of human immunodeficiency virus type 1 (HIV-1) infection. This indication is based in results of clinical trials, but patients who participate in these studies usually are greatly motivated to continue their prescribed regimen, and can be different from the "real life". Therefore, clinical practice often cannot reproduce published results.

Methods: A retrospective longitudinal cohort study was performed with 36 naïve-treatment patients, who started therapy with LPV/r or EFZ, with follow-up of 36 months. The primary endpoint was virological success (HIV RNA <50 copies/mL) in the first six months and at the end of the study. Effectiveness was examined comparing time to virological failure and CD4 recovery.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HIV-1 infected naive-treatment patients

排除标准

  • use of Anti-Retroviral Agents in the past

研究组 & 干预措施

Efavirenz Group

Active Comparator

Naïve-treatment HIV patients, who started therapy with Efavirenz

干预措施: First-line Antiretroviral Therapy (Drug)

Lopinavir/r Group

Active Comparator

Naïve-treatment HIV patients, who started therapy with Lopinavir/ritonavir

干预措施: First-line Antiretroviral Therapy (Drug)

结局指标

主要结局

Maintenance HIV RNA <50 copies/mL at the end oh 36 months

时间窗: 36 months

次要结局

  • Achieve HIV RNA <50 copies/mL at the first 6 months(6 months)

研究者

发起方
UPECLIN HC FM Botucatu Unesp
申办方类型
Other

研究点 (1)

Loading locations...

相似试验